Quick Answer
Evofem Biosciences, Inc. reported Operating Income of -$7.68 million for fiscal year 2024.
Evofem Biosciences, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$7.68M | +57.0% |
| 2023 | -$17.85M | +78.8% |
| 2022 | -$84.12M | +49.6% |
| 2021 | -$166.80M | -61.0% |
| 2020 | -$103.62M | -96.5% |
| 2019 | -$52.74M | +32.1% |
| 2018 | -$77.64M | -117.6% |
| 2017 | -$35.69M | -196.3% |
| 2016 | -$12.04M | +71.4% |
| 2015 | -$42.05M | -338.4% |
| 2014 | -$9.59M | +33.5% |
| 2013 | -$14.42M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $951.0K | +139.0% | +176.0% |
| June 30, 2025 | -$1.25M | +9.9% | -482.6% |
| March 31, 2025 | $327.0K | +111.5% | +113.4% |
| September 30, 2024 | -$2.44M | +31.3% | -75.7% |
| June 30, 2024 | -$1.39M | +81.1% | +51.2% |
| March 31, 2024 | -$2.84M | +20.5% | +19.9% |
| September 30, 2023 | -$3.55M | +81.0% | +51.6% |
| June 30, 2023 | -$7.34M | +70.0% | -105.0% |
- Evofem Biosciences, Inc. showed an increase of +57.0% in Operating Income compared to the prior fiscal year.
- Over the 2013–2024 period, Evofem Biosciences, Inc.’s operating income has grown by 46.8% (from -$14.42 million to -$7.68 million).
- The most recent figure is from Evofem Biosciences, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: